Dosimetrically administered nebulized morphine for breathlessness in very severe chronic obstructive pulmonary disease: A randomized, controlled trial

13Citations
Citations of this article
78Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Systemic morphine has evidence to support its use for reducing breathlessness in patients with severe chronic obstructive pulmonary disease (COPD). The effectiveness of the nebulized route, however, has not yet been confirmed. Recent studies have shown that opioid receptors are localized within epithelium of human trachea and large bronchi, a target site for a dosimetric nebulizer. The aim of this study was to compare any clinical or statistical differences in breathlessness intensity between nebulized 2.0% morphine and 0,9% NaCl in patients with very severe COPD. Methods: The study was a double-blind, controlled, cross-over trial. Participants received morphine or NaCl during two 4-day periods. Sequence of periods was randomized. The primary outcome measure was reduction of breathlessness intensity now by ≥20 mm using a 100 mm visual analogue scale (VAS) at baseline, 15, 30, 60, 120, 180 and 240 min after daily administration, during normal activities. Results: Ten of 11 patients included completed the study protocol. All patients experienced clinically and statistically significant (p < 0.0001) breathlessness reduction during morphine nebulization. Mean VAS changes for morphine and 0.9% NaCl periods were 25.4 mm (standard deviation (SD): 9.0; median: 23,0; range: 14.0 to 41,5; confidence interval (CI): 95%) and 6.3 mm (SD: 7.8; median: 6.8; range: -11,5 to 19,5; CI: 95%), respectively. No treatment emergent adverse effects were noted. Discussion: Our study showed superiority of dosimetrically administered nebulized morphine compared to NaCl in reducing breathlessness. This may have been achieved through morphine's direct action on receptors in large airways, although a systemic effect from absorption through the lungs cannot be excluded. Trial registration: Retrospectively registered (07.03.2017), ISRCTN14865597

References Powered by Scopus

Interpretative strategies for lung function tests

4736Citations
N/AReaders
Get full text

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary

4200Citations
N/AReaders
Get full text

An official American thoracic society/European respiratory society statement: Key concepts and advances in pulmonary rehabilitation

2905Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Opioids for breathlessness: A narrative review

38Citations
N/AReaders
Get full text

Endogenous opiates and behavior: 2017

18Citations
N/AReaders
Get full text

Efficacy and Safety of Topical Morphine: A Narrative Review

9Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Janowiak, P., Krajnik, M., Podolec, Z., Bandurski, T., Damps-Konstańska, I., Sobański, P., … Jassem, E. (2017). Dosimetrically administered nebulized morphine for breathlessness in very severe chronic obstructive pulmonary disease: A randomized, controlled trial. BMC Pulmonary Medicine, 17(1). https://doi.org/10.1186/s12890-017-0535-y

Readers over time

‘18‘19‘20‘21‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

71%

Researcher 3

14%

Lecturer / Post doc 2

10%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

50%

Nursing and Health Professions 9

32%

Pharmacology, Toxicology and Pharmaceut... 3

11%

Psychology 2

7%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 32

Save time finding and organizing research with Mendeley

Sign up for free
0